Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, Massachusetts
- Most recent report
- 10-Q, filed Nov 4, 2026
- Incorporated
- Delaware
- Filings on record
- 64 filings
- On EDGAR
- CIK 2096997
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
Financials 3
News 4
Prospectuses and Registrations 4
Ownership 8 of 47
- 4 Insider reported a trade Sep 9, 2026
- 3 Insider reported their initial holding Sep 9, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 5, 2026
- 4 Insider reported a trade Jul 8, 2026
- 3 Insider reported their initial holding Jul 8, 2026
- 4 Insider reported a trade Jun 11, 2026
Other 6
- EFFECT Notice that a registration became effective Apr 16, 2026
- S-1MEF Apr 16, 2026
- CERT Exchange certified a listing Apr 15, 2026
- 8-A12B Registration of a security for exchange listing Apr 14, 2026
- DRS/A Draft registration statement, submitted confidentially, amended Feb 11, 2026
- DRS Draft registration statement, submitted confidentially Dec 19, 2025
Everything here comes from Kailera Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.